Group 1 - PepGen Inc. has successfully closed its underwritten public offering of 35,937,500 shares of common stock [1] - The offering included the full exercise of the underwriters' option to purchase an additional 4,687,500 shares [1] - The company is focused on developing next-generation oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases [1]

Group 1 - PepGen Inc. is a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases [1] - The company announced the pricing of an underwritten offering of 31,250,000 shares of its common stock at a public price of $3.20 per share [1] - The aggregate gross proceeds from this offering are expected to be $100 million before deducting any expenses [1]